goliath suspensionskoncentrat
adama northern europe b.v. - metamitron - suspensionskoncentrat - 700 g/l metamitron
skater suspensionskoncentrat
adama northern europe b.v. - metamitron - suspensionskoncentrat - 700 g/l metamitron
asulox (disp. 2022) vandopløseligt koncentrat
upl europe ltd. (tidligere: united phosphorus ltd.) - asulam - vandopløseligt koncentrat - 400 g/l asulam
asulox (disp. 2023) vandopløseligt koncentrat
upl europe ltd. (tidligere: united phosphorus ltd.) - asulam - vandopløseligt koncentrat - 400 g/l asulam
darzalex
janssen-cilag international n.v. - daratumumab - multipelt myelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. i kombination med bortezomib, thalidomid og dexamethason til behandling af voksne patienter med nyligt diagnosticeret med myelomatose, der er berettiget til autolog stamcelletransplantation. i kombination med lenalidomid og dexamethason, eller bortezomib og dexamethason til behandling af voksne patienter med myelomatose, som har modtaget mindst én tidligere behandling. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. som monoterapi til behandling af voksne patienter med recidiverende og refraktær myelomatose, hvis tidligere behandling indgår en proteasome-hæmmer og et immunmodulerende agent, og som har vist, sygdommens progression på den sidste terapi. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
sileo
orion corporation - dexmedetomidine hydrochloride - nervesystemet, andre sovemidler og beroligende midler - hunde - lindring af akut angst og frygt, der er forbundet med støj hos hunde.
beloukha emulsionskoncentrat
certis belchim b.v. - pelargonsyre - emulsionskoncentrat - 680 g/l pelargonsyre
teppeki vanddispergerbart granulat
isk biosciences products inc. - flonicamid - vanddispergerbart granulat - 500 g/kg flonicamid
ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinale stromale tumorer - andre antineoplastiske midler, protein kinase hæmmere - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
zenby suspensionskoncentrat
isk biosciences products inc. - isofetamid - suspensionskoncentrat - 400 g/l isofetamid